Affinage

MYBBP1A

Myb-binding protein 1A · UniProt Q9BQG0

Length
1328 aa
Mass
148.9 kDa
Annotated
2026-06-10
100 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MYBBP1A is a predominantly nucleolar protein that functions as a stress-sensing transcriptional co-repressor coupling ribosome biogenesis status to p53 activation and cell fate (PMID:9447996, PMID:21297583). Within the nucleolus it associates with the RNA Polymerase I transcription complex and ribosome biogenesis machinery, repressing rRNA gene transcription and reducing Pol I loading on rDNA while also being required for pre-rRNA processing (PMID:22645127), and it maintains silenced rDNA repeats through association with HDAC1/2 and preservation of DNA methylation and histone silencing marks (PMID:22686419). MYBBP1A is tethered to the nucleolus by nucleolar RNA; when rRNA transcription falls during nucleolar stress, nucleolar RNA content drops and MYBBP1A translocates to the nucleoplasm (PMID:21297583), where it acts as a self-assembling platform that directly binds the p53 C-terminal regulatory domain to promote p53 tetramerization and p300-mediated acetylation, driving p21/BAX induction and apoptosis (PMID:21297583, PMID:24375404). The nature of the nucleolar insult determines outcome: graded loss of rRNA transcription drives translocation, p53 acetylation and apoptosis, whereas processing inhibition that preserves nucleolar RNA retains MYBBP1A in the nucleolus and yields p53 accumulation without acetylation and G1 arrest (PMID:26044764). Beyond p53, MYBBP1A is a direct repressor of multiple transcription factors: it binds and represses PGC-1α to limit mitochondrial respiration (PMID:14744933), represses c-MYB transactivation via its N-terminal Myb-binding region (PMID:9447996, PMID:31066170), and competes with p300 for the RelA/p65 transactivation domain to repress NF-κB before pre-initiation complex formation (PMID:17196614). It also acts as a co-repressor on the Per2 circadian promoter in concert with CRY1 and H3K9 dimethylation (PMID:19129230). Consistent with these growth-restraining activities, MYBBP1A is essential for early mouse embryonic development and behaves as a tumor suppressor whose loss increases susceptibility to Ras-induced transformation (PMID:23056166). MYBBP1A is phosphorylated by Aurora B at serine 1303 during mitosis, with its depletion causing spindle assembly defects and mitotic delay (PMID:20177074), and its protein abundance is regulated post-transcriptionally through NAT10-mediated ac4C modification of its mRNA (PMID:38583415).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1998 High

    Established MYBBP1A as a nucleolar protein with defined transcription-factor-binding architecture, answering where it resides and what it binds.

    Evidence Molecular cloning, immunofluorescence, and transactivation assays mapping the N-terminal Myb-binding region

    PMID:9447996

    Open questions at the time
    • Did not establish how nucleolar localization relates to function
    • Physiological role of proteolytic p67 fragment unclear
  2. 2004 High

    Identified MYBBP1A as a direct repressor of PGC-1α, linking it to metabolic/mitochondrial control and to a p38 MAPK regulatory switch.

    Evidence Reciprocal co-IP, adenoviral overexpression in myoblasts, mitochondrial respiration and reporter assays

    PMID:14744933

    Open questions at the time
    • Binding interface on PGC-1α not mapped
    • Whether repression occurs at promoter chromatin not addressed
  3. 2006 High

    Defined a co-repressor mechanism for NF-κB, showing MYBBP1A competes with p300 rather than blocking RelA nuclear entry or DNA binding.

    Evidence In vitro transcription from chromatinized templates plus co-IP competition assays

    PMID:17196614

    Open questions at the time
    • Endogenous NF-κB target genes not profiled
    • Stimulus dependence of repression untested
  4. 2007 High

    Showed MYBBP1A extends its co-repressor role to homeodomain factor Prep1 and that actinomycin D-driven nucleoplasmic translocation enables endogenous interaction.

    Evidence Reciprocal co-IP, in vitro competition with Pbx1, binding-motif mutagenesis, and reporter assays

    PMID:17875935

    Open questions at the time
    • Functional consequence on broader Hox program unclear
    • Translocation trigger mechanism not yet defined
  5. 2008 High

    Resolved MYBBP1A into distinct full-length and processed complexes and linked ribosome-biogenesis stress to its proteolytic processing and nucleolar-to-nucleoplasmic relocation.

    Evidence Biochemical complex purification with mass spectrometry, immunofluorescence, and processing immunoblots under actinomycin D/cisplatin/UV

    PMID:18173745

    Open questions at the time
    • Protease responsible for processing not identified
    • Functional difference between complexes not fully defined
  6. 2008 High

    Genetic mouse model placed MYBBP1A downstream of Prep1 in metabolic control, showing Prep1 controls p160 stability to set PGC-1α/GLUT4 levels and insulin sensitivity.

    Evidence Prep1-hypomorphic mice with in vivo and L6 cell p160 rescue and glucose uptake assays

    PMID:18644868

    Open questions at the time
    • Mechanism by which Prep1 stabilizes p160 unknown
    • Tissue specificity of metabolic effect not fully delineated
  7. 2010 High

    Connected MYBBP1A to mitosis by identifying it as an Aurora B substrate at S1303 required for proper spindle assembly.

    Evidence In vitro kinase assay with MS phosphosite mapping, Aurora inhibitor/knockdown, and RNAi mitotic phenotyping

    PMID:20177074

    Open questions at the time
    • Downstream effector of S1303 phosphorylation unknown
    • Link between mitotic and nucleolar functions unresolved
  8. 2011 High

    Defined the core stress-sensing mechanism: nucleolar RNA tethers MYBBP1A, and its loss triggers translocation that promotes p53–p300 interaction and acetylation.

    Evidence RNAi (including RPL5/RPL11), localization imaging, p53-p300 co-IP, and p53 acetylation immunoblots

    PMID:21297583

    Open questions at the time
    • RNA species mediating tethering not molecularly defined
    • How translocation rate is sensed not quantified
  9. 2012 High

    Demonstrated MYBBP1A regulates rRNA synthesis itself, repressing Pol I transcription and being required for pre-rRNA processing, and maintains rDNA silencing via HDAC1/2.

    Evidence Pol I co-IP and ChIP, Pol I reporter assays, rRNA precursor analysis, bisulfite/methylation analysis with knockdown

    PMID:22645127 PMID:22686419

    Open questions at the time
    • How repressive versus processing roles are partitioned unclear
    • Recruitment to active versus silent rDNA not fully mapped
  10. 2012 High

    Established the organismal and tumor-suppressor importance of MYBBP1A through embryonic lethality, mitotic defects, and increased Ras-transformation susceptibility upon loss.

    Evidence Conditional knockout, siRNA with cell-cycle and expression profiling, mitotic imaging, and transformation assays

    PMID:23056166

    Open questions at the time
    • Essential function driving embryonic lethality not pinpointed
    • Whether tumor suppression is p53-dependent not isolated
  11. 2013 High

    Provided the structural logic for p53 activation: MYBBP1A self-assembles and binds the p53 C-terminus to template tetramer formation required for acetylation and death.

    Evidence In vitro binding, deletion mapping, size-exclusion tetramer analysis, and actinomycin D cell-death assays

    PMID:24375404

    Open questions at the time
    • No high-resolution structure of the platform
    • Stoichiometry of self-assembly not defined
  12. 2013 Medium

    Extended the chromatin/p53 axis through interactions with Sirt7 (inhibiting H3K18 deacetylation) and p53 under anoikis, where MYBBP1A loss promotes tumorigenesis.

    Evidence Co-IP, deletion mapping, deacetylation assays, and anoikis/colony/xenograft assays in p53-WT breast cancer cells

    PMID:23388179 PMID:24134843

    Open questions at the time
    • Sirt7 interaction lacks in vivo functional follow-up
    • Anoikis effect not mechanistically tied to a specific p53 target set
  13. 2015 High

    Distinguished two nucleolar stress modes, showing graded rRNA transcription loss (not processing inhibition) drives MYBBP1A translocation, p53 acetylation, and apoptosis versus G1 arrest.

    Evidence RNAi against transcription versus processing factors with paired localization, acetylation, p21/BAX, and flow-cytometry readouts

    PMID:26044764

    Open questions at the time
    • Threshold of nucleolar RNA loss that flips the switch not quantified
    • Generality across cell types not established
  14. 2019 Medium

    Linked MYBBP1A to renal cancer metabolism and stemness through dual repression of PGC-1α and c-MYB and to hepatocellular IGF/AKT signaling via DNMT1-dependent IGFBP5 silencing.

    Evidence siRNA knockdown with metabolic, sphere, and xenograft assays; co-IP, ChIP, and bisulfite sequencing for DNMT1/IGFBP5

    PMID:30781655 PMID:31066170 PMID:31109829

    Open questions at the time
    • Context-dependence on c-MYB levels not generalized
    • DNMT1 recruitment mechanism to IGFBP5 not defined
  15. 2024 Medium

    Added post-transcriptional and lncRNA layers of control: NAT10 ac4C modification stabilizes MYBBP1A mRNA to drive p53/SLC7A11-dependent ferroptosis, and GAS5 lncRNA stabilizes p53 by binding MYBBP1A.

    Evidence ac4C assay, stability immunoblots, co-IP, RNA-IP, ferroptosis/reporter assays, and in vivo cardiac I/R and tumor models

    PMID:38583415 PMID:38762546

    Open questions at the time
    • ac4C site on MYBBP1A mRNA not mapped
    • GAS5 binding region on MYBBP1A undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the diverse co-repressor activities, mitotic phosphorylation, and nucleolar stress-sensing are integrated into a single regulatory program remains unresolved.
  • No structural model of the MYBBP1A p53-tethering platform
  • Molecular identity of the nucleolar RNA tether unknown
  • Whether mitotic and nucleolar functions share a common regulatory logic untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 2 GO:0060090 molecular adaptor activity 2 GO:0003723 RNA binding 1
Localization
GO:0005730 nucleolus 4 GO:0005634 nucleus 2 GO:0005654 nucleoplasm 2
Pathway
R-HSA-74160 Gene expression (Transcription) 5 R-HSA-5357801 Programmed Cell Death 3 R-HSA-1640170 Cell Cycle 2 R-HSA-4839726 Chromatin organization 2 R-HSA-8953854 Metabolism of RNA 2 R-HSA-8953897 Cellular responses to stimuli 2
Partners
CRY1DNMT1EP300PPARGC1APREP1RELASIRT7TP53
Complex memberships
MYBBP1A-ribosomal subunit large complexRNA Polymerase I transcription complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 MYBBP1A (p160 Myb-binding protein) was cloned and found to localize predominantly in the nucleolus by immunofluorescence. The p67 N-terminal fragment (generated by proteolytic cleavage in some cell types) but not full-length p160 can inhibit transactivation by c-Myb, indicating that the Myb-binding site lies within the N-terminal 580 residues and the Jun-binding site is C-terminal to that region. Molecular cloning, immunofluorescence localization, transactivation assays, proteolytic cleavage characterization Molecular and cellular biology High 9447996
2004 MYBBP1A (p160MBP) was identified as a direct repressor of PGC-1alpha. MYBBP1A binds PGC-1alpha and suppresses its transcriptional activity, reducing mitochondrial respiration and electron transport gene expression in myoblasts. p38 MAPK phosphorylation of PGC-1alpha disrupts the MYBBP1A–PGC-1alpha interaction, providing a mechanism for p38-mediated activation of PGC-1alpha. Co-immunoprecipitation, adenoviral overexpression in myoblasts, mitochondrial respiration assay, reporter assays Genes & development High 14744933
2006 MYBBP1A acts as a co-repressor of NF-κB by directly binding the transcription activation domain of RelA/p65. MYBBP1A repressed NF-κB-dependent transcription from chromatinized templates in vitro at a step before pre-initiation complex formation without affecting RelA/p65 nuclear translocation or DNA binding. MYBBP1A competed with the histone acetyltransferase p300 for interaction with the RelA/p65 transactivation domain. Co-immunoprecipitation, in vitro transcription from chromatinized templates, reporter assays, competition binding assays Journal of molecular biology High 17196614
2007 MYBBP1A (p160) interacts with the homeodomain transcription factor Prep1 and competes with Pbx1 for Prep1 binding in vitro. The N-terminal p67 fragment of p160 binds the HR1 domain of Prep1 at residues LFPLL (L63/L66). MYBBP1A inhibits Prep1-dependent HoxB2 expression. Actinomycin D-induced translocation of p160 from the nucleolus to the nucleoplasm promotes endogenous co-localization and co-immunoprecipitation with Prep1. Co-immunoprecipitation, in vitro competition binding, reporter assays, immunofluorescence co-localization, mutagenesis of Prep1 binding motif Molecular and cellular biology High 17875935
2008 MYBBP1A (Mybbp1a) is present in two distinct complexes in cells: a smaller complex containing the processed p67/p140 fragments (lacking nucleolar localization sequences) and a larger complex containing intact p160 associated with ribosomal subunits. Treatment with actinomycin D, cisplatin, or UV (all inhibitors of ribosome biogenesis) induced proteolytic processing of p160 into p140 and p67 and caused translocation of Mybbp1a from the nucleolus to the nucleoplasm. Both complexes contain nucleophosmin and nucleolin; nucleostemin is only in the large complex. Biochemical purification of complexes, mass spectrometry, immunofluorescence, western blot of processed forms Genes to cells : devoted to molecular & cellular mechanisms High 18173745
2009 MYBBP1A functions as a co-repressor on the Period2 (Per2) circadian clock gene promoter by interacting with mouse CRY1 (mCRY1). Chromatin immunoprecipitation showed endogenous Mybbp1a binding to the Per2 promoter temporally coinciding with mCRY1 binding and correlated with down-regulation of Per2 expression and dimethylation of histone H3 Lys9. Affinity purification of mCRY1 complexes, co-immunoprecipitation, reporter assays, chromatin immunoprecipitation (ChIP) Nucleic acids research High 19129230
2010 MYBBP1A is a substrate of Aurora B kinase; serine 1303 was identified as the major phosphorylation site by mass spectrometry. MYBBP1A is phosphorylated at S1303 in nocodazole-arrested mitotic cells and dephosphorylated upon Aurora B silencing or treatment with the Aurora kinase inhibitor Danusertib. Depletion of MYBBP1A by RNAi causes mitotic progression delay and spindle assembly defects. In vitro kinase assay, mass spectrometry identification of phosphosite, RNAi knockdown with mitotic phenotype, inhibitor treatment The Journal of biological chemistry High 20177074
2011 MYBBP1A is tethered to the nucleolus through nucleolar RNA. Upon nucleolar stress (suppression of rRNA transcription), nucleolar RNA content decreases, MYBBP1A translocates from the nucleolus to the nucleoplasm, and then facilitates p53–p300 interaction to enhance p53 acetylation and p53 accumulation. Depletion of RPL5 or RPL11 blocked rRNA export, maintained nucleolar RNA levels, and thereby prevented MYBBP1A translocation and p53 activation. RNAi knockdown, immunofluorescence tracking of MYBBP1A localization, co-immunoprecipitation of p53-p300 complex, western blot of p53 acetylation The EMBO journal High 21297583
2011 Quantitative proteomics identified MYBBP1A (p160 Myb-binding protein) as a novel substrate/target of the VHL ubiquitin ligase complex, suggesting VHL regulates MYBBP1A protein levels. Quantitative proteomics (SILAC-based ubiquitin ligase substrate identification) PloS one Low 21386990
2012 MYBBP1A is essential for early mouse embryonic development (required prior to blastocyst formation). In HeLa cells, MYBBP1A down-regulation promotes apoptosis, causes G2/M arrest or anomalous mitosis, and affects expression of genes controlling chromosomal segregation. At mitosis, MYBBP1A localizes to a parachromosomal region. In NIH3T3 cells, MYBBP1A down-regulation increases susceptibility to Ras-induced transformation, indicating tumor suppressor activity. Conditional knockout (embryonic lethal phenotype), siRNA knockdown, gene-expression profiling, cell cycle analysis, immunofluorescence at mitosis, transformation assay PloS one High 23056166
2012 Mybbp1a associates with the RNA Polymerase I transcription complex and ribosome biogenesis machinery. Mybbp1a represses rRNA gene transcription (shown by reporter assay decoupling transcription from processing) and reduces RNA Pol I loading on rDNA genes (ChIP). Depletion of Mybbp1a causes accumulation of unprocessed rRNA precursor and growth arrest, indicating a dual role in rRNA transcription repression and pre-rRNA processing. Co-immunoprecipitation with Pol I complex, ChIP for Pol I loading, Pol I reporter assay, siRNA knockdown with rRNA precursor analysis The Journal of biological chemistry High 22645127
2012 Mybbp1a binds to the chromatin around hypermethylated/inactive rDNA gene promoters and maintains rDNA repeats in a silenced state by associating with HDAC1/2. Knockdown of Mybbp1a abrogates local DNA methylation and histone silencing marks, displaces UBF and HDACs from the promoter, and elevates rRNA expression. ChIP, siRNA knockdown, bisulfite sequencing/methylation analysis, western blot Journal of biomedical science Medium 22686419
2013 MYBBP1A enhances p53 tetramerization and subsequent p300-mediated acetylation in response to nucleolar stress. MYBBP1A has two regions that directly bind lysine residues of the p53 C-terminal regulatory domain. MYBBP1A forms self-assembled complexes that provide a molecular platform for p53 tetramer formation, and tetramerization is required for efficient p53 acetylation and cell death. Co-immunoprecipitation, in vitro binding assays, size-exclusion chromatography for tetramer analysis, deletion mapping, cell death assays with actinomycin D The Journal of biological chemistry High 24375404
2013 MYBBP1A binds to Sirt7 in vitro and in vivo (co-IP), and inhibits Sirt7-mediated deacetylation of histone H3K18. The N- and C-terminal regions of Sirt7 and the C-terminal region of Mybbp1a are required for this interaction. Co-immunoprecipitation (in vivo), in vitro binding assay, serial deletion mapping, histone deacetylation assay Biochemical and biophysical research communications Medium 24134843
2013 MYBBP1A binds p53 and enhances p53 target gene transcription under anoikis conditions. MYBBP1A knockdown in breast cancer cells with wild-type p53 (MCF-7, ZR-75-1) enhanced tumorigenesis, colony formation, and anoikis resistance. Co-immunoprecipitation, siRNA knockdown, colony formation assay, xenograft assay, anoikis assay BMC cancer Medium 23388179
2014 ANK (progressive ankylosis protein) interacts with MYBBP1a via its cytoplasmic C-terminal loop. MYBBP1a nuclear levels are regulated by the ANK interaction; loss of ANK/MYBBP1a interaction (in ank/ank chondrocytes) increases nuclear MYBBP1a, decreases NF-κB activity, and reduces catabolic marker expression and cartilage degradation in IL-1β-treated chondrocytes. Yeast two-hybrid screening, co-immunoprecipitation, immunohistochemistry/immunoblotting for MYBBP1a nuclear/cytoplasmic distribution, NF-κB reporter assay, transfection with mutant ank constructs Osteoarthritis and cartilage Medium 24747173
2015 Gradual reduction in rRNA transcription (not rRNA processing inhibition) triggers MYBBP1A translocation from the nucleolus to the nucleoplasm. MYBBP1A translocation correlates with increased p53 acetylation, p21 and BAX induction, and apoptosis. In contrast, when rRNA processing is inhibited (nucleolar RNA levels maintained), MYBBP1A remains in the nucleolus, p53 accumulates without acetylation, and cells undergo G1 arrest rather than apoptosis. RNAi depletion of rRNA transcription/processing factors, immunofluorescence for MYBBP1A localization, western blot for p53 acetylation and p21/BAX, flow cytometry for cell cycle/apoptosis Scientific reports High 26044764
2019 MYBBP1A directly represses PGC-1α and also represses c-MYB, which in turn regulates PGC-1α mRNA levels. Loss of MYBBP1A simultaneously relieves both modes of repression, causing a metabolic switch from glycolysis to OXPHOS in renal cancer cells. This effect is selective to cells expressing high c-MYB levels. siRNA knockdown, gene expression analysis, metabolic assays (glycolysis vs OXPHOS), xenograft models Molecular oncology Medium 31066170
2019 MYBBP1A loss increases c-MYB transcriptional activity, leading to expansion of the cancer stem cell population in renal carcinoma cells expressing high c-MYB. This increases tumorigenic properties in vitro and in vivo. siRNA knockdown, stem cell sphere assay, xenograft, gene expression analysis Cancers Medium 30781655
2019 MYBBP1A forms a complex with DNMT1 (shown by co-IP) and induces aberrant hypermethylation of CpG islands in the IGFBP5 promoter, suppressing IGFBP5 secretion and thereby activating the IGF1/AKT signaling pathway in hepatocellular carcinoma cells. Co-immunoprecipitation, ChIP, bisulfite sequencing/pyrosequencing for CpG methylation, siRNA knockdown with proliferation/migration readout EBioMedicine Medium 31109829
2024 NAT10 induces ac4C modification of Mybbp1a mRNA, increasing Mybbp1a protein stability. Elevated Mybbp1a in turn activates p53 and represses transcription of the anti-ferroptotic gene SLC7A11, promoting cardiomyocyte ferroptosis during ischemia/reperfusion injury. Knockdown of Mybbp1a partially abolished the detrimental effects of NAT10 overexpression on ferroptosis. ac4C RNA modification assay, western blot for Mybbp1a stability, co-immunoprecipitation, siRNA knockdown, ferroptosis assay, cardiac I/R mouse model with cardiomyocyte-specific NAT10 KO Redox biology Medium 38583415
2024 GAS5 lncRNA stabilizes p53 by directly binding to MYBBP1A and facilitating the MYBBP1A–p53 interaction, enhancing p53-mediated transcription of IRF1 and activating type I interferon signaling (CXCL10, CCL5 production) in NSCLC cells. RNA immunoprecipitation, co-immunoprecipitation, reporter assays, overexpression/knockdown experiments, in vivo tumor models Cell death discovery Medium 38762546
1999 Human MYBBP1A cDNA was cloned; the protein was mapped to chromosome 17p13.3 by FISH. The gene physically links with the ALOX15 gene locus. cDNA cloning, fluorescence in situ hybridization (FISH), radiation hybrid mapping Genomics Medium 10644447
2008 In Prep1-hypomorphic mice, reduced Prep1 causes reduced p160 (MYBBP1A) protein levels in skeletal muscle (Prep1 controls p160 protein stability). This reduction in p160 increases PGC-1α and GLUT4 expression in muscle, enhancing insulin sensitivity and glucose uptake. Overexpression of p160 (but not Pbx1) in L6 muscle cells or in vivo reversed the phenotype, confirming that p160 mediates the Prep1 effect on PGC-1α/GLUT4. Hypomorphic mouse model, in vivo muscle delivery of p160 cDNA, L6 cell overexpression, glucose uptake assay, gene expression analysis Molecular and cellular biology High 18644868

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Molecular and cellular biology 777 8816443
1995 Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (New York, N.Y.) 548 7604264
2009 Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature reviews. Cancer 405 19701241
2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular endocrinology (Baltimore, Md.) 399 12805412
2002 Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 369 11823864
1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Molecular endocrinology (Baltimore, Md.) 321 9773983
2001 Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. The Journal of biological chemistry 297 11050077
2004 Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes & development 255 14744933
2000 Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Human molecular genetics 208 10607837
1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Molecular and cellular biology 207 10454556
2000 Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. The Journal of biological chemistry 201 11010967
2000 Regulation of somatic growth by the p160 coactivator p/CIP. Proceedings of the National Academy of Sciences of the United States of America 167 11087842
2002 Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Molecular and cellular biology 165 12024042
1998 p160 RhoA-binding kinase ROKalpha induces neurite retraction. The Journal of biological chemistry 164 9446546
2000 The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Molecular and cellular biology 158 10733574
1999 Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. The Journal of biological chemistry 157 10497186
2001 Coronary smooth muscle differentiation from proepicardial cells requires rhoA-mediated actin reorganization and p160 rho-kinase activity. Developmental biology 138 11784072
2003 Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proceedings of the National Academy of Sciences of the United States of America 123 12589022
2003 Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Molecular endocrinology (Baltimore, Md.) 123 12714702
2001 Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. The Journal of biological chemistry 117 11301320
2003 CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Molecular cell 110 14690606
2001 Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. The Journal of biological chemistry 110 11551963
2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. The Journal of biological chemistry 105 11893728
2000 Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. The Journal of biological chemistry 104 10934189
2004 Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. The Journal of biological chemistry 100 15184363
2006 The competence factor beta Ftz-F1 potentiates ecdysone receptor activity via recruiting a p160/SRC coactivator. Molecular and cellular biology 90 17015464
2002 A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. The Journal of clinical endocrinology and metabolism 88 12050230
2004 Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. The Journal of biological chemistry 81 14747462
2002 A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1alpha-induced lymphocyte actomyosin and microtubular organization and chemotaxis. Journal of immunology (Baltimore, Md. : 1950) 80 11751986
1998 Molecular cloning reveals that the p160 Myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by Myb. Molecular and cellular biology 78 9447996
2009 Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clinical cancer research : an official journal of the American Association for Cancer Research 75 19276281
1999 Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. Implications for the recruitment of TRAP and p160 coactivator complexes. The Journal of biological chemistry 72 10037764
2005 Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Molecular endocrinology (Baltimore, Md.) 70 16081517
2002 Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. The Journal of biological chemistry 66 12114525
2011 RNA content in the nucleolus alters p53 acetylation via MYBBP1A. The EMBO journal 65 21297583
2003 Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation. Molecular endocrinology (Baltimore, Md.) 63 12893881
2005 Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clinical cancer research : an official journal of the American Association for Cancer Research 61 16166451
2006 Structural diversity in p160/CREB-binding protein coactivator complexes. The Journal of biological chemistry 60 16540468
2006 MYBBP1a is a novel repressor of NF-kappaB. Journal of molecular biology 60 17196614
2005 The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis 60 15917309
2004 Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB-binding protein. Protein science : a publication of the Protein Society 58 14691235
2008 Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology 57 19095746
2004 Role of p160 coactivator complex in the activation of liver X receptor. Arteriosclerosis, thrombosis, and vascular biology 57 14764426
2007 Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 55 18059336
1993 BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene 53 8423987
2015 Minireview: nuclear receptor coregulators of the p160 family: insights into inflammation and metabolism. Molecular endocrinology (Baltimore, Md.) 52 25647480
2002 Tumor necrosis factor alpha receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators. The Journal of biological chemistry 52 12477726
2024 The positive feedback loop of the NAT10/Mybbp1a/p53 axis promotes cardiomyocyte ferroptosis to exacerbate cardiac I/R injury. Redox biology 49 38583415
2007 The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action. Oncogene 49 17968310
2003 The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. The Journal of biological chemistry 49 12970370
2006 Coregulator exchange and sphingosine-sensitive cooperativity of steroidogenic factor-1, general control nonderepressed 5, p54, and p160 coactivators regulate cyclic adenosine 3',5'-monophosphate-dependent cytochrome P450c17 transcription rate. Molecular endocrinology (Baltimore, Md.) 47 17121866
2006 p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Molecular endocrinology (Baltimore, Md.) 46 16410316
1993 Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL. Blood 46 8353288
2001 Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex. The Journal of biological chemistry 45 11704662
2014 A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. The Journal of clinical endocrinology and metabolism 44 24483153
2007 p160 Myb-binding protein interacts with Prep1 and inhibits its transcriptional activity. Molecular and cellular biology 42 17875935
2004 Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells. Molecular endocrinology (Baltimore, Md.) 40 15331759
2012 Identification of genetic associations of SP110/MYBBP1A/RELA with pulmonary tuberculosis in the Chinese Han population. Human genetics 39 23129390
2012 Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. The international journal of biochemistry & cell biology 39 23270728
2005 Differential recruitment of p160 coactivators by glucocorticoid receptor between Schwann cells and astrocytes. Molecular endocrinology (Baltimore, Md.) 39 16179382
2009 Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. The Journal of biological chemistry 38 19828458
2008 Ribosomal stress induces processing of Mybbp1a and its translocation from the nucleolus to the nucleoplasm. Genes to cells : devoted to molecular & cellular mechanisms 38 18173745
2012 Myb-binding protein 1A (MYBBP1A) is essential for early embryonic development, controls cell cycle and mitosis, and acts as a tumor suppressor. PloS one 37 23056166
2008 Prep1 deficiency induces protection from diabetes and increased insulin sensitivity through a p160-mediated mechanism. Molecular and cellular biology 37 18644868
2006 Regulation of Nrf2 transactivation domain activity by p160 RAC3/SRC3 and other nuclear co-regulators. Journal of biochemistry and molecular biology 36 16756760
2005 Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. The Journal of biological chemistry 36 15767262
2014 The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction. Biology of reproduction 35 25297546
2012 Myb-binding protein 1a (Mybbp1a) regulates levels and processing of pre-ribosomal RNA. The Journal of biological chemistry 35 22645127
2003 Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. The Journal of biological chemistry 34 12540843
1983 Cloning and analysis of reverse transcript P160 genomes of Abelson murine leukemia virus. Journal of virology 34 6300457
2015 miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Molecular endocrinology (Baltimore, Md.) 33 26066330
2009 Molecular characterization of Mybbp1a as a co-repressor on the Period2 promoter. Nucleic acids research 32 19129230
2002 Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. Molecular endocrinology (Baltimore, Md.) 32 12403846
1990 P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells. Oncogene 32 2140598
2013 The nucleolar protein Myb-binding protein 1A (MYBBP1A) enhances p53 tetramerization and acetylation in response to nucleolar disruption. The Journal of biological chemistry 31 24375404
2006 Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 31 16741308
2024 NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis. Cell death discovery 30 38762546
2020 The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness. Cancers 29 31968688
2015 Gradual reduction in rRNA transcription triggers p53 acetylation and apoptosis via MYBBP1A. Scientific reports 29 26044764
2013 MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis. BMC cancer 28 23388179
2013 Inhibition of H3K18 deacetylation of Sirt7 by Myb-binding protein 1a (Mybbp1a). Biochemical and biophysical research communications 28 24134843
1994 The immunodominant Eimeria acervulina sporozoite antigen previously described as p160/p240 is a 19-kilodalton antigen present in several Eimeria species. Molecular and biochemical parasitology 28 8183325
2004 FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors. The Journal of steroid biochemistry and molecular biology 26 15698540
2019 Targeting Mybbp1a suppresses HCC progression via inhibiting IGF1/AKT pathway by CpG islands hypo-methylation dependent promotion of IGFBP5. EBioMedicine 24 31109829
2012 Epigeneitc silencing of ribosomal RNA genes by Mybbp1a. Journal of biomedical science 24 22686419
2011 Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressor. PloS one 23 21386990
2010 Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase. The Journal of biological chemistry 23 20177074
2008 Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. The Prostate 20 18780293
2014 Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells. PloS one 19 24695638
2016 Mapping the interactions of adenoviral E1A proteins with the p160 nuclear receptor coactivator binding domain of CBP. Protein science : a publication of the Protein Society 18 27699893
2009 The p160 coactivator PAS-B motif stabilizes nuclear receptor binding and contributes to isoform-specific regulation by thyroid hormone receptors. The Journal of biological chemistry 18 19487700
2008 P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain. Nucleic acids research 18 18267973
2004 Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery 18 15300201
1999 Molecular cloning and chromosomal mapping of the human homologue of MYB binding protein (P160) 1A (MYBBP1A) to 17p13.3. Genomics 18 10644447
2019 c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer. Molecular oncology 17 31066170
2014 The role of ANK interactions with MYBBP1a and SPHK1 in catabolic events of articular chondrocytes. Osteoarthritis and cartilage 17 24747173
2012 Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells. BMC cancer 17 22339894
2001 p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation 17 11560856
2019 Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer. Cancers 16 30781655
2004 Proteolytic cleavage of the cell surface protein p160 is required for detachment of the fertilization envelope in the sea urchin. Developmental biology 16 15242800

Missed literature

Know a paper Affinage missed for MYBBP1A? Flag it for the maintainers and the community.

No submissions yet.